Antiemetic Drugs Market Trends, Size, Competitive Analysis and Forecast 2021-2027

The global antiemetic drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Antiemetic drugs are the medications that are used to treat nausea and vomiting. Both of these conditions are generally the symptoms of several medical issues such as food poisoning, pregnancy, motion sickness, dizziness, and sometimes even emotional stress. Adding to this, antiemetics drugs are also used for the treatment of the side effects of other medications such as chemotherapy, opioid analgesics, and general anesthetics.

Further, growing geriatric population along with the rising prevalence of cancer as well as the growing number of gastroenteritis patients are also acting as the pivotal factors contributing to the increased demand for these drugs. The global antiemetic drugs market is also driven by extensive R&D along with new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is an antiemetic drug that is indicated for the control of severe nausea and vomiting.

To Request a Sample of our Report on Antiemetic Drugs Market: https://www.omrglobal.com/request-sample/antiemetic-drugs-market

Some major players in the market include GlaxoSmithKline plc, Merck & Co., Inc., and Novartis International AG, among others. These market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered-

· By Drug Class

· By Application

• Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

• Competitive Landscape: GlaxoSmithKline plc, Merck & Co., Inc., and Novartis International AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Antiemetic Drugs Market is Available @ https://www.omrglobal.com/industry-reports/antiemetic-drugs-market

Global Antiemetic Drugs Market Report by Segment

By Drug Class

• 5-HT3 Receptor Antagonists

• Dopamine Antagonists

• NK1 Receptor Antagonists

• H1 Receptor Antagonists

• Cannabinoids

• Benzodiazepines

• Anticholinergics

• Steroids

By Application

• Motion Sickness

• Dizziness

• General Anesthetics

• Others

Global Antiemetic Drugs Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.